TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest announcement is out from Active Biotech AB ( (SE:ACTI) ).
Active Biotech has provided a status update on its development programs for laquinimod and tasquinimod. Laquinimod has shown promising results in delivering therapeutic concentrations to the back of the eye, addressing the need for non-invasive treatments for inflammatory eye diseases. The company is seeking a commercial partnership for further development. For tasquinimod, recruitment for myelofibrosis studies is temporarily paused to amend protocols, but the company remains optimistic about the timelines. Recent data supports tasquinimod’s potential in myelofibrosis, with full study results to be published soon.
More about Active Biotech AB
Active Biotech AB is a biotechnology company focused on developing first-in-class immunomodulatory treatments for oncology and immunology indications with high unmet medical needs. The company has three main projects: tasquinimod for hematological malignancies like myelofibrosis, laquinimod for inflammatory eye disorders, and naptumomab, an anti-cancer immunotherapy. Active Biotech’s core focus is on tasquinimod’s development in myelofibrosis, a rare blood cancer, while laquinimod is being developed for non-infectious uveitis.
Average Trading Volume: 33,398,890
Current Market Cap: SEK230.3M
For detailed information about ACTI stock, go to TipRanks’ Stock Analysis page.